Citations

Showing 10 of 107969 citations.

Cyclic Bicytopenia in a Patient with Shapiro Syndrome
Roeker, Lindsey E. , Gupta, Vinay , Wolanskyj, Alexandra P., Gangat, Naseema , Gonsalves, Wilson I. , Roeker, Lindsey

Mayo Clinic

Case Reports in Hematology | September 25, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/231713 | PMID 24187634 Get It

Shapiro syndrome and periodic hypothermia have been reported approximately fifty times in the literature. Shapiro syndrome is defined as the constellation of periodic hypothermia and hyperhidrosis along with agenesis of the corpus callosum by Shapiro et al. in 1969. Periodic hypothermia is a more broad diagnosis with a number of proposed mechanisms; it occurs in patients without structural brain abnormalities. Hematologic abnormalities beyond iron-deficiency anemia have not been documented in any of the reported cases of Shapiro syndrome or periodic hypothermia. Though accidental and therapeutic hypothermia have been associated with thrombocytopenia, this is, to our knowledge, the first reported case of periodic intrinsic hypothermia causing bicytopenia. In this report, we present the case of a patient with Shapiro syndrome who experienced cyclic bicytopenia mirroring hypothermic episodes. We address the differential diagnosis of bicytopenia, review the mechanisms proposed for cytopenias related to hypothermia, and propose possible mechanisms for the finding in this case.
Familial Aggregation of High Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus
Mangale, Dorothy I. , Kariuki, Silvia N. , Chrabot, Beverly S, Kumabe, Marissa, Kelly, Jennifer A. , Harley, John B., Sivils, Kathy L., Niewold, Timothy B. , James, Judith A.

Mayo Clinic

Clinical and Developmental Immunology | September 25, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-6

10.1155/2013/267430 | PMID 24187561 Get It

Systemic lupus erythematosus (SLE) patients frequently have high circulating tumor necrosis factor alpha (TNF-α) levels. We explored circulating TNF-αlevels in SLE families to determine whether high levels of TNF-αwere clustered in a heritable pattern. We measured TNF-αin 242 SLE patients, 361 unaffected family members, 23 unaffected spouses of SLE patients, and 62 unrelated healthy controls. Familial correlations and relative recurrence risk rates for the high TNF-αtrait were assessed. SLE-affected individuals had the highest TNF-αlevels, and TNF-αwas significantly higher in unaffected first degree relatives than healthy unrelated subjects(P=0.0025). No Mendelian patterns were observed, but 28.4% of unaffected first degree relatives of SLE patients had high TNF-αlevels, resulting in a first degree relative recurrence risk of 4.48(P=2.9×10-5). Interestingly, the median TNF-αvalue in spouses was similar to that of the first degree relatives. Concordance of the TNF-αtrait (high versus low) in SLE patients and their spouses was strikingly high at 78.2%. These data support a role for TNF-αin SLE pathogenesis, and TNF-αlevels may relate with heritable factors. The high degree of concordance in SLE patients and their spouses suggests that environmental factors may also play a role in the observed familial aggregation.
Faculty Opinions recommendation of Immune clearance of highly pathogenic SIV infection.
Badley, Andrew D. , Cummins, Nathan W. , Badley, Andrew D

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 25, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718106971.793483846 Get It

Response to Comment on: Chakkera et al. Can New-Onset Diabetes After Kidney Transplant Be Prevented? Diabetes Care 2013;36:1406–1412
Chakkera, Harini A. , Pham, Phuong-Thu, Pomeroy, Jeremy , Weil, E. Jennifer , Knowler, William C. , Pham, Phuong‐Thu T., Chakkera, Harini A

Mayo Clinic

Diabetes Care | September 25, 2013 | Volume: 36 | Issue: 10 | Pages: e183-e183

10.2337/dc13-1656 | PMID 24065856 Get It

Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder
Gillingham, Melanie B. , Schoeller, Dale A. , Matern, Dietrich , Purnell, Jonathan Q. , Harding, Cary O. , Gillingham, Melanie B

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | September 25, 2013 | Volume: 305 | Issue: 10 | Pages: E1299-E1308

10.1152/ajpendo.00225.2013 | PMID 24064340 Get It

The development of insulin resistance has been associated with impaired mitochondrial fatty acid oxidation (FAO), but the exact relationship between FAO capacity and glucose metabolism continues to be debated. To address this controversy, patients with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) deficiency underwent an oral glucose tolerance test (OGTT) and measurement of energy expenditure, body composition, and plasma metabolites. Compared with controls, patients with LCHAD deficiency had a trend toward higher total body fat and extramyocellular lipid deposition but similar levels of intramyocelluar and intrahepatic lipids. Resting energy expenditure was similar between the groups, but respiratory quotient was higher and total energy expenditure was lower in LCHAD-deficient patients compared with controls. High-molecular-weight (HMW) adiponectin levels were lower and plasma long-chain acylcarnitines were higher among LCHAD-deficient patients. Fasting and post-OGTT levels of glucose, insulin, and ghrelin, along with estimates of insulin sensitivity, were the same between the groups. Despite decreased capacity for FAO, lower total energy expenditure and plasma HMW adiponectin, and increased plasma acylcarnitines, LCHAD-deficient patients exhibited normal glucose tolerance. These data suggest that inhibition of the FAO pathway in humans is not sufficient to induce insulin resistance.
Statistical Design for Biospecimen Cohort Size in Proteomics-based Biomarker Discovery and Verification Studies
Skates, Steven J. , Gillette, Michael A. , Carr, Steven A. , Anderson, Leigh, Liebler, D.C. , Ransohoff, David F. , Rifai, Nader , Kondratovich, Marina, Težak, Živana , Mansfield, Elizabeth, Oberg, Ann L. , Barnes, Grady , Mesri, Mehdi , Kinsinger, Christopher R. , Rodriguez, Henry , Boja, Emily S. , LaBaer, Joshua , Wright, Ian , Gail, Mitchell H.

Mayo Clinic

Journal of Proteome Research | September 25, 2013 | Volume: 12 | Issue: 12 | Pages: 5383-5394

10.1021/pr400132j | PMID 24063748 Get It

Insulin and the Lung: Connecting Asthma and Metabolic Syndrome
Singh, Suchita, Prakash, Y. S. , Linneberg, Allan , Agrawal, Anurag , Prakash, Y S

Mayo Clinic

Journal of Allergy | September 25, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-8

10.1155/2013/627384 | PMID 24204385 Get It

Obesity, metabolic syndrome, and asthma are all rapidly increasing globally. Substantial emerging evidence suggests that these three conditions are epidemiologically and mechanistically linked. Since the link between obesity and asthma appears to extend beyond mechanical pulmonary disadvantage, molecular understanding is necessary. Insulin resistance is a strong, independent risk factor for asthma development, but it is unknown whether a direct effect of insulin on the lung is involved. This review summarizes current knowledge regarding the effect of insulin on cellular components of the lung and highlights the molecular consequences of insulin-related metabolic signaling cascades that could adversely affect lung structure and function. Examples include airway smooth muscle proliferation and contractility and regulatory signaling networks that are associated with asthma. These aspects of insulin signaling provide mechanistic insight into the clinical evidence for the links between obesity, metabolic syndrome, and airway diseases, setting the stage for novel therapeutic avenues targeting these conditions.
New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Yadav, Anitha, Chang, Yu‐Hui , Aqel, Bashar , Byrne, Thomas , Chakkera, Harini A. , Douglas, David D., Rakela, Jorge , Vargas, Hugo E. , Carey, Elizabeth J. , Yadav, Anitha D, Aqel, Bashar A. , Mulligan, David C. , Vargas, Hugo E , Chakkera, Harini A , Chang, Yu-Hui

Mayo Clinic

Journal of Transplantation | September 24, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-7

10.1155/2013/269096 | PMID 24205434 Get It

New onset diabetes after transplantation (NODAT) occurs less frequently in living donor liver transplant (LDLT) recipients than in deceased donor liver transplant (DDLT) recipients. The aim of this study was to compare the incidence and predictive factors for NODAT in LDLT versus DDLT recipients. The Organ Procurement and Transplant Network/United Network for Organ Sharing database was reviewed from 2004 to 2010, and 902 LDLT and 19,582 DDLT nondiabetic recipients were included. The overall incidence of NODAT was 12.2% at 1 year after liver transplantation. At 1, 3, and 5 years after transplant, the incidence of NODAT in LDLT recipients was 7.4, 2.1, and 2.6%, respectively, compared to 12.5, 3.4, and 1.9%, respectively, in DDLT recipients. LDLT recipients have a lower risk of NODAT compared to DDLT recipients (hazard ratio = 0.63 (0.52–0.75),P<0.001). Predictors for NODAT in LDLT recipients were hepatitis C (HCV) and treated acute cellular rejection (ACR). Risk factors in DDLT recipients were recipient male gender, recipient age, body mass index, donor age, donor diabetes, HCV, and treated ACR. LDLT recipients have a lower incidence and fewer risk factors for NODAT compared to DDLT recipients. Early identification of risk factors will assist timely clinical interventions to prevent NODAT complications.
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength
Randall, Connor, Bridges, Daniel , Nogués, Xavier , Torres, Elisa, Mellibovsky, Leonardo , Hoffseth, Kevin , Stalbaum, Tyler, Srikanth, Ananya, Weaver, James C. , Rosen, Sasha, Barnard, H. R. , Brimer, Davis, Proctor, Alex, Candy, James V., Saldaña, Christopher , Chandrasekar, Srinivasan , Lescun, Timothy B. , Nielson, Carrie M. , Herthel, D. J., Kopeikin, Hal, Yang, Henry T. Y., McCready, Louise K., Khosla, Sundeep , Hansma, Paul K. , Güerri‐Fernández, Robert , Puig, Lluís , Orwoll, Eric , Farr, Joshua N. , Díez‐Pérez, Adolfo , Khosla, Sundeep

Mayo Clinic

Journal of Medical Devices | September 24, 2013 | Volume: 7 | Issue: 4 | Pages: No page available

10.1115/1.4024829 | PMID 24115973 Get It

A novel, hand-held Reference Point Indentation (RPI) instrument, measures how well the bone of living patients and large animals resists indentation. The results presented here are reported in terms of Bone Material Strength, which is a normalized measure of how well the bone resists indentation, and is inversely related to the indentation distance into the bone. We present examples of the instrument's use in: (1) laboratory experiments on bone, including experiments through a layer of soft tissue, (2) three human clinical trials, two ongoing in Barcelona and at the Mayo Clinic, and one completed in Portland, OR, and (3) two ongoing horse clinical trials, one at Purdue University and another at Alamo Pintado Stables in California. The instrument is capable of measuring consistent values when testing through soft tissue such as skin and periosteum, and does so handheld, an improvement over previous Reference Point Indentation instruments. Measurements conducted on horses showed reproducible results when testing the horse through tissue or on bare bone. In the human clinical trials, reasonable and consistent values were obtained, suggesting the Osteoprobe® is capable of measuring Bone Material Strength in vivo, but larger studies are needed to determine the efficacy of the instrument's use in medical diagnosis.